United States
Print page content Print
Increase text size Decrease text size
Text Size

Introducing
SILEO®

(dexmedetomidine oromucosal gel)

VETERINARIAN FAQs (PDF)

Download
Sign in to Order** If you are a customer in Hawaii, please contact your local Zoetis Sales Representative or Hawaii Mega-Cor to place your order.

A simple approach to a complex problem: the first and only FDA-approved medication indicated for the treatment of canine noise aversion.

SILEO® (dexmedetomidine oromucosal gel) is an oromucosal gel formulation of dexmedetomidine hydrochloride provided in a 3 mL syringe at a concentration of 0.1 mg/mL. Using the syringe, SILEO is easily administered between the cheek and gum, allowing for transmucosal absorption. Because SILEO is formulated to provide a low dose of dexmedetomidine, the dog remains calm, yet fully functional, and is able to interact normally with the family.

SILEO

The name, pronounced /si-lehh-o/, is a Latin word meaning to “be silent.”

Practical for Your Clients

  • Calming without sedating, allowing for normal dog-owner interactions
  • Easy to administer at home, when needed
  • Works on its own without any other treatments or training

Relief for Your Patients

  • Quick onset of action
  • Supports early intervention for optimal effect on the quality of life of the dog8

Confidence for You and Your Team

  • Proven to be safe and effective in a randomized, placebo-controlled clinical trial
  • An easy treatment for a challenging condition
  • Comprehensive pet owner education resources

VETERINARIAN FAQs (PDF)

Download
Sign in to Order** If you are a customer in Hawaii, please contact your local Zoetis Sales Representative or Hawaii Mega-Cor to place your order.

Important Safety Information: Do not use SILEO in dogs with severe cardiovascular disease, respiratory, liver or kidney diseases, or in conditions of shock, severe debilitation, or stress due to extreme heat, cold or fatigue or in dogs hypersensitive to dexmedetomidine or to any of the excipients. SILEO should not be administered in the presence of preexisting hypotension, hypoxia, or bradycardia. Do not use in dogs sedated from previous dosing. SILEO has not been evaluated in dogs younger than 16 weeks of age or in dogs with dental or gingival disease that could have an effect on the absorption of SILEO. SILEO has not been evaluated for use in breeding, pregnant, or lactating dogs or for aversion behaviors to thunderstorms. Transient pale mucous membranes at the site of application may occur with SILEO use. Other uncommon adverse reactions included emesis, drowsiness or sedation. Handlers should avoid direct exposure of SILEO to their skin, eyes or mouth. Failure to lock the ring-stop on the syringe before dosing SILEO could potentially lead to an accidental overdose. Always review INSTRUCTIONS FOR USE before dispensing and dosing. See full Prescribing Information.

References

  • 8. Overall, K. Manual of Clinical Behavioral Medicine for Dogs and Cats. St. Louis, MO: Elsevier Health Sciences, 2013:650-654.